A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of kidney disease that causes fluid-filled cysts to develop in the kidneys. The purpose of this study is to assess...
A Study to See Iftolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old withAutosomal Recessive Polycystic Kidney Disease (ARPKD)
To evaluate the safety of tolvaptan in pediatric subjects with ARPKD...
A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
The primary objective of this study is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney disease (ARPKD)...
Top Cities for Polycystic Kidney Disease Clinical Trials
Polycystic Kidney Disease clinical trials are recruiting across 21 cities. Here are the cities with the most active studies:
About Polycystic Kidney Disease
Polycystic kidney disease (PKD) is a genetic disorder causing numerous fluid-filled cysts to grow in the kidneys, leading to kidney enlargement and progressive loss of function. Autosomal dominant PKD is the most common form. Treatment includes tolvaptan and management of complications.
Clinical trials are advancing new treatments for polycystic kidney disease. Currently, 3 studies are recruiting a combined 280 participants across the United States. Research is being conducted by 2 organizations including AbbVie, Otsuka Pharmaceutical Development & Commercialization, Inc..
2026 Polycystic Kidney Disease Research Landscape
As of March 2026, the polycystic kidney disease clinical trial landscape includes 3 actively recruiting studies across 21 cities in the United States. These studies are collectively seeking 280 participants, with an average enrollment target of 93 per study.
Research is being led by 2 different organizations, including AbbVie, Otsuka Pharmaceutical Development & Commercialization, Inc..
Geographically, polycystic kidney disease trials are most concentrated in Rochester, Minnesota (3 trials); Washington D.C., District of Columbia (2 trials); Atlanta, Georgia (2 trials); Chicago, Illinois (2 trials); Baltimore, Maryland (2 trials) and 7 other cities.
Featured Polycystic Kidney Disease Studies
Highlighted recruiting studies for polycystic kidney disease, selected by enrollment size and research scope.
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of kidney disease that causes fluid-filled cysts to develop in the kidneys. The purpose of this study is to assess the safety and efficacy of ABBV-CLS-628 for the treatment of ADPKD in adult participants. ABBV-CLS-628 is an investigational drug being developed for the treatment of ADPKD. Participants are placed ...
A Study to See Iftolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old withAutosomal Recessive Polycystic Kidney Disease (ARPKD)
To evaluate the safety of tolvaptan in pediatric subjects with ARPKD
A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
The primary objective of this study is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney disease (ARPKD)
Frequently Asked Questions About Polycystic Kidney Disease Clinical Trials
Are there polycystic kidney disease clinical trials near me?
Yes, there are 3 polycystic kidney disease clinical trials currently recruiting across 21+ cities in the United States, including Rochester, Minnesota; Washington D.C., District of Columbia; Atlanta, Georgia. Browse the studies above to find one at a location convenient for you.
How do I join a polycystic kidney disease clinical trial?
To join a polycystic kidney disease clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are polycystic kidney disease clinical trials free?
Yes, participation in polycystic kidney disease clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of polycystic kidney disease treatments are being studied?
Current polycystic kidney disease clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 2 research organizations.
Is it safe to participate in polycystic kidney disease clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov